Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proteomic analysis of extracellular vesicles released from endothelial cells in vitro reveals increased levels of E-selectin and dual specificity phosphatase 7 as a potential marker of TNFα-mediated apoptosis.

PloS one·2026
Same author

Recombinant von Willebrand Factor (vonicog alfa) reduces platelet inhibition caused by antiplatelet drugs and has potential as an acute haemostatic agent.

Haematologica·2026
Same author

Platelet Membrane Receptors and Signalling Pathways.

Handbook of experimental pharmacology·2025
Same author

Improved micro-sampling methodology enables accurate platelet function analysis.

Platelets·2025
Same author

A computational framework for the investigation of phosphoinositide regulation.

PLoS computational biology·2025
Same author

Extended Modelling of Molecular Calcium Signalling in Platelets by Combined Recurrent Neural Network and Partial Least Squares Analyses.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Jun 19, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

PECAM-1 expression and activity negatively regulate multiple platelet signaling pathways.

Chris I Jones1, Stephen F Garner, Leonardo A Moraes

  • 1Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, Berkshire RG6 6UB, UK. c.i.jones@reading.ac.uk

FEBS Letters
|October 24, 2009
PubMed
Summary

Platelet endothelial cell adhesion molecule-1 (PECAM-1) inhibits platelet activation by collagen, ADP, and thrombin. This combined inhibition significantly reduces thrombus formation, impacting blood clot development.

More Related Videos

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Related Experiment Videos

Last Updated: Jun 19, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Area of Science:

  • Biomedical Science
  • Hematology
  • Molecular Biology

Background:

  • Platelet endothelial cell adhesion molecule-1 (PECAM-1) is known to inhibit platelet response to collagen.
  • Its inhibitory effects on responses to ADP and thrombin are less understood.
  • Understanding PECAM-1's multifaceted role is crucial for thrombosis research.

Purpose of the Study:

  • To investigate the combined inhibitory effects of PECAM-1 on platelet activation by collagen, ADP, and thrombin.
  • To determine if PECAM-1 signaling significantly impacts thrombus formation.
  • To explore the relationship between PECAM-1 surface expression and platelet agonist response.

Main Methods:

  • Assessing platelet aggregation in response to various agonists (CRP-XL, ADP, thrombin).
  • Analyzing the effect of PECAM-1 surface expression levels on platelet activation.
  • Investigating the impact of PECAM-1 clustering on platelet signaling pathways.
  • Quantifying thrombus formation under conditions of varying PECAM-1 activity.

Main Results:

  • A negative correlation was observed between PECAM-1 surface expression and platelet response to CRP-XL and ADP.
  • PECAM-1 clustering demonstrated an inhibitory effect on platelet responses to CRP-XL, ADP, and thrombin.
  • The combined inhibition of these multiple platelet activation pathways led to a significant reduction in thrombus formation.

Conclusions:

  • PECAM-1 plays a significant inhibitory role in multiple platelet activation pathways.
  • Combined PECAM-1-mediated inhibition of collagen, ADP, and thrombin signaling markedly reduces thrombus formation.
  • These findings highlight PECAM-1 as a potential therapeutic target for preventing thrombosis.